Rigel: Strengthening Commercial Trajectory, Clear Path to 2026 Profitability, and Advancing Pipeline Support Buy Rating

Rigel, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $57.00 price target.

Joseph Pantginis has given his Buy rating due to a combination of factors tied to Rigel’s near‑term commercial performance and longer‑term financial outlook. He highlights that management’s 2026 guidance appears realistic, underpinned by stronger‑than‑expected product sales across Tavalisse, Rezlidhia, and Gavreto, which collectively drive revenue above his prior forecasts. The company’s expectation of achieving positive net income in 2026, combined with a solid projected cash position, is seen as providing sufficient financial flexibility to continue investing in internal programs without jeopardizing profitability. In his updated model, these operational and financial improvements translate into higher earnings estimates, reinforcing the case for additional share price appreciation.

Pantginis also points to the advancing pipeline as an important contributor to Rigel’s valuation and upside potential. The R289 program in relapsed/refractory LR-MDS is progressing through Phase 1b, with dose expansion, Phase 2 dose selection, and an FDA discussion around a potential registrational trial all targeted for 2026, supported by encouraging early safety and activity. In parallel, new data for Gavreto from the TAPISTRY study demonstrate meaningful and durable responses in RET fusion–positive gastrointestinal tumors, supporting its role as a tissue‑agnostic targeted therapy with a manageable safety profile. Together, the combination of growing commercial revenue, a path to sustained profitability, and value‑creating clinical assets underpins his conviction that Rigel’s shares remain attractively positioned, justifying his Buy rating.

In another report released today, TipRanks – Anthropic also reiterated a Buy rating on the stock with a $50.00 price target.